TRIUMPH I: Double Blind Placebo Controlled Clinical Investigation Into the Efficacy and Tolerability of Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Registrational; Therapeutic Use
- Acronyms TRIUMPH I
- Sponsors United Therapeutics Corporation
Most Recent Events
- 21 Jan 2025 According to United Therapeutics Corporation Media Release, data from the study will be presented at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress taking place January 29 through February 1, 2025 in Rio de Janeiro.
- 13 Sep 2023 Primary endpoint (Peak 6-minute Walk Distance) has been met according to results presented at the 33rd Annual Congress of the European Respiratory Society.
- 13 Sep 2023 Results of post hoc analysis assessing To explore the effects of inhaled treprostinil (iTre) on PAH patients with 1 cardiovascular comorbidity in the pivotal TRIUMPH study presented at the 33rd Annual Congress of the European Respiratory Society